Compare DORM & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DORM | TNGX |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.1B |
| IPO Year | 1996 | 2020 |
| Metric | DORM | TNGX |
|---|---|---|
| Price | $137.43 | $22.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $158.13 | $47.09 |
| AVG Volume (30 Days) | 248.7K | ★ 4.5M |
| Earning Date | 10-26-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.14 | ★ 26.89 |
| EPS | ★ 6.33 | N/A |
| Revenue | ★ $2,130,319,000.00 | $62,384,000.00 |
| Revenue This Year | $2.70 | N/A |
| Revenue Next Year | $4.71 | N/A |
| P/E Ratio | $22.50 | ★ N/A |
| Revenue Growth | 6.03 | ★ 48.29 |
| 52 Week Low | $98.45 | $7.49 |
| 52 Week High | $155.37 | $34.39 |
| Indicator | DORM | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 61.66 | 44.10 |
| Support Level | $131.63 | $20.46 |
| Resistance Level | $143.16 | $22.01 |
| Average True Range (ATR) | 5.68 | 1.92 |
| MACD | 1.45 | -0.20 |
| Stochastic Oscillator | 70.61 | 11.19 |
Dorman Products Inc is a supplier of original equipment parts for automobiles. It offers automotive and heavy-duty replacement parts, automotive hardware, brake parts, and fasteners for the automotive and heavy-duty aftermarket. The products are sold under the Dorman brand and its sub-brands OE Solutions, Help!, Conduct-Tite, Super ATV, etc., through aftermarket retailers, warehouse distributors, specialty markets, and salvage yards. The company operates through three business segments, which include Light Duty, Heavy Duty, and Specialty Vehicle. A majority of its revenue is generated from the Light Duty segment, which designs and markets replacement parts and fasteners mainly for passenger cars and light trucks. Geographically, it derives key revenue from the United States.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.